Biogen's stock soars as Alzheimer's drug costs revealed after FDA approval

Biogen's stock soars as Alzheimer's drug costs revealed after FDA approval Biogen Inc. shares were on track for their biggest gain on record after the drugmaker released pricing for its recently approved Alzheimer’s drug Aduhelm. https://ift.tt/3w2UrEL https://ift.tt/32Pjpcl Markets June 8, 2021 at 12:12AM